BrightPath Biotherapeutics Co., Ltd.
4594.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.78B
Close$
Share Statistics
| Market cap | $3.78 Billion |
|---|---|
| Enterprise Value | $2.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.7 |
| Beta | 1.3 |
| Outstanding Shares | 138,891,219 |
Return
| Return on Equity | -87.44% |
|---|---|
| Return on Assets | -78.72% |
| Return on Invested Capital | -84.75% |
Valuation & Multiples
| P/E Ratio | -3.52 |
|---|---|
| PEG | -2.95 |
| Price to Sales | - |
| Price to Book Ratio | 3.46 |
| Enterprise Value to Revenue | 35470.58 |
| Enterprise Value to EBIT | -1.37 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BrightPath Biotherapeutics Co., Ltd.
42 employees
CEO: Kenichi Nagai BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I...